Question

I am a breastfeeding mother and i want to know if it is safe to use NSC 165560? Is NSC 165560 safe for nursing mother and child? Does NSC 165560 extracts into breast milk? Does NSC 165560 has any long term or short term side effects on infants? Can NSC 165560 influence milk supply or can NSC 165560 decrease milk supply in lactating mothers?

NSC 165560 lactation summary

NSC 165560 usage has low risk in breastfeeding
  • DrLact safety Score for NSC 165560 is 3 out of 8 which is considered Low Risk as per our analyses.
  • A safety Score of 3 indicates that usage of NSC 165560 may cause some minor side effects in breastfed baby.
  • Our study of different scientific research indicates that NSC 165560 may cause moderate to no side effects in lactating mother.
  • Most of scientific studies and research papers declaring usage of NSC 165560 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
  • While using NSC 165560 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About NSC 165560 usage in lactation

Prostaglandin E2 is eventually used for induction of labor at term. Orally or vaginally administrated. At latest update no published data on excretion into breast milk were found.Pharmacokinetic data (very rapid removal and moderately high protein binding capacity) make it highly unlikely the passage into breast milk in significant amounts.It is a natural component of breast milk (Alzina 1986 Neu 1988) that increases in concentration in the first week postpartum (Hawkes 1999) and possibly plays an important role in the gastrointestinal function of the infant (Bedrick 1989, Shimizu 1992) and intestinal motility (Lucas 1980, Li 1994). Although NSC 165560 can be used to inhibit lactation by reducing prolactin levels (Bremme 1980, England 1988, Toppozada 1992), it would be necessary to achieve a higher dose than that used at the time of partum for several days (Berić 1992). It would not be recommended to use it for relief of breast engorgement in women who are willing to breastfeed.The effect of reducing prolactin levels induced by NSC 165560 only occurs during the first days postpartum (Caminiti 1980).

Answer by DrLact: About NSC 165560 usage in lactation

NSC 165560 (prostaglandin E2) has not been measured in human milk after exogenous administration, but it is a normal component of breastmilk in small amounts where it may help protect the infant's gastrointestinal tract. Use of vaginal NSC 165560 to induce labor appears to have a negative effect on breastfeeding. Given orally in the first few days postpartum, NSC 165560 can suppress lactation. Whether postpartum vaginal or endocervical administration suppresses lactation is not known, but it should probably not be used postpartum in mothers who wish to breastfeed. By one month postpartum, the drug appears not to suppress lactation.

NSC 165560 Possible Effects in Breastfeeding

A retrospective cohort study of birth records in Cardiff, Wales, UK found that the use of vaginal prostaglandins for the induction of labor resulted in an 11% decrease in the likelihood that mothers would be breastfeeding at 48 hours postpartum. The subgroup of first-time mothers had a 15% decrease.[10] A nonrandomized prospective study compared women who had spontaneous deliveries with those who had elective induction using NSC 165560 vaginal gel. At hospital discharge, exclusive breastfeeding rates were similar between the two groups (88% and 89%). However, at 1 and 3 months postpartum, exclusive breastfeeding rates were significantly lower in mothers who had NSC 165560 induction than in those who delivered spontaneously. Exclusive breastfeeding rates were 54% and 85% at 1 month and 46% and 59% at 3 months postpartum, respectively. Rates of supplemental and exclusive formula feeding were higher in the induced mothers at both time points also.[11] NSC 165560 has been used investigationally to inhibit postpartum lactation and engorgement by reducing serum prolactin concentrations.[12][13][14][15][16] The effect on prolactin levels, engorgement and lactation appears to be dose and duration related. Oral dosages of 3 mg daily for 4 days[17] or 0.5 mg three times daily were ineffective,[16] whereas oral dosages of 8 to 12 mg over 24 to 30 hours were effective.[12][14] These effects seem to be limited to the first few days postpartum; NSC 165560 had no effect on serum prolactin or milk production when given to women 30 days postpartum.[12] Compared to oral bromocriptine 2.5 mg every 12 hours for 14 days, NSC 165560 12 mg orally in divided doses over 30 hours was as effective as bromocriptine, but resulted in less rebound breast tenderness.[14]
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.